Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients

Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) is a promising immunotherapeutic approach for patients with advanced solid tumors. While numerous advances have been made, the contribution of neoantigen-specific CD4+T cells within TIL infusion products remains undere...

Full description

Bibliographic Details
Main Authors: Shari Pilon-Thomas, Daniel Abate-Daga, Amod A. Sarnaik, James J. Mule, Xiaoqing Yu, Patrick Innamarato, Jamie Blauvelt, Holly Branthoover, Jake Ceccarelli, TJ Langer, MacLean S. Hall, Jamie K. Teer, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Amy M. Hall, Carolyn J. Rich, Allison D. Richards, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, John E. Mullinax
Format: Article
Language:English
Published: BMJ Publishing Group 2023-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/10/e007288.full

Internet

https://jitc.bmj.com/content/11/10/e007288.full

Similar Items